GSK plc (GSK)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 39.07 |
| Open | 39.63 |
| Bid | 39.72 x 2200 |
| Ask | 40.00 x 800 |
| Day's range | 39.59 - 40.12 |
| 52-week range | 33.67 - 45.93 |
| Volume | |
| Avg. volume | 3,606,919 |
| Market cap | 81.277B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 14.19 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.49 (3.74%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- Business Wire
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
PHILADELPHIA, July 11, 2024--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA).
- Business Wire
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
- Business Wire
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer
© 2024 Yahoo. All rights reserved.